secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001708599-25-000023
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina presents non-immunogenic POZ-lipid data at ACS 2025 meeting
------------------------------------------------------------------

- Randall Moreadith, M.D., Ph.D., Chief Development Officer, presented at ACS Spring 2025 in San Diego.
- Presentation titled 'A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles'.
- In rats, POZ-lipid did not trigger IgM or IgG antibody response after repeat dosing.
- In contrast, PEG-lipid standards elicited a strong and boosted antibody response.
- Non-immunogenic POZ-lipid could enable safer LNP formulations for gene therapy and RNA medicines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000023/0001708599-25-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000023/ser-20250324.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer